Glucose Regulation During Risperidone and Olanzapine Treatment
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/2/2016 |
| Contact: | John Newcomer, M.D. |
| Email: | newcomej@psychiatry.wustl.edu |
| Phone: | 1-314-362-2459 |
The overall purpose of this research is to look at how two of the most commonly prescribed
newer antipsychotic medications, risperidone and olanzapine, affect substances in the body
such as glucose and insulin. Undesirable changes in blood sugar control, or glucose
regulation, and type 2 diabetes can occur more commonly in individuals with schizophrenia
compared to healthy subjects and subjects with other psychiatric conditions. While
abnormalities in glucose regulation were first reported in schizophrenia before the
introduction of antipsychotic medications, antipsychotic treatment may contribute
significantly to abnormalities in glucose regulation. Attention to the way that
antipsychotic medications may affect glucose regulation has increased as doctors have become
more concerned in general about disease- and drug-related medical complications, including
weight gain during antipsychotic treatment.
newer antipsychotic medications, risperidone and olanzapine, affect substances in the body
such as glucose and insulin. Undesirable changes in blood sugar control, or glucose
regulation, and type 2 diabetes can occur more commonly in individuals with schizophrenia
compared to healthy subjects and subjects with other psychiatric conditions. While
abnormalities in glucose regulation were first reported in schizophrenia before the
introduction of antipsychotic medications, antipsychotic treatment may contribute
significantly to abnormalities in glucose regulation. Attention to the way that
antipsychotic medications may affect glucose regulation has increased as doctors have become
more concerned in general about disease- and drug-related medical complications, including
weight gain during antipsychotic treatment.
This study will include 70 patients diagnosed with schizophrenia, taking either risperidone,
olanzapine or haloperidol, and 20 healthy control subjects. Each subject will undergo a 4
hour glucose tolerance test. In addition, there will be a small project within the overall
study to measure the effects of risperidone and olanzapine on glucose regulation as the
individuals switch from their prior treatment with a conventional antipsychotic medication
to either risperidone or olanzapine. Ten subjects will be studied on a typical neuroleptic
at baseline then switched over a one week period to risperidone or olanzapine. The
participants will be evaluated at 1 week, 4 weeks, and 12 weeks, prospectively. Each
evaluation will consist of a 4 hour glucose tolerance test.
olanzapine or haloperidol, and 20 healthy control subjects. Each subject will undergo a 4
hour glucose tolerance test. In addition, there will be a small project within the overall
study to measure the effects of risperidone and olanzapine on glucose regulation as the
individuals switch from their prior treatment with a conventional antipsychotic medication
to either risperidone or olanzapine. Ten subjects will be studied on a typical neuroleptic
at baseline then switched over a one week period to risperidone or olanzapine. The
participants will be evaluated at 1 week, 4 weeks, and 12 weeks, prospectively. Each
evaluation will consist of a 4 hour glucose tolerance test.
Inclusion Criteria:
- meet DSM-IV criteria for schizophrenia, any type, or schizoaffective disorder;
- able to give informed consent;
- no medication changes for 2 weeks prior to and during the period of study;
- currently taking olanzapine, risperidone, haloperidol or another typical
antipsychotic
We found this trial at
1
site
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials
